Imvotamab Biosimilar – Anti-CD3E;MS4A1 mAb – Research Grade

Imvotamab Biosimilar: A Novel Anti-CD3E,MS4A1 Monoclonal Antibody

Imvotamab Biosimilar is a research grade monoclonal antibody that specifically targets the CD3E and MS4A1 proteins. This novel antibody has been developed as a biosimilar of the well-known anti-CD3 monoclonal antibody, OKT3, which is used in the treatment of various autoimmune diseases and transplant rejection. Imvotamab Biosimilar has a similar structure and activity to OKT3, but with improved efficacy and reduced side effects.

Structure of Imvotamab Biosimilar

Imvotamab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains of Imvotamab Biosimilar are specifically designed to bind to the CD3E and MS4A1 proteins, making it a highly specific therapeutic agent.

The constant domains of Imvotamab Biosimilar are responsible for the effector functions of the antibody, such as complement activation and antibody-dependent cellular cytotoxicity (ADCC). These functions are important for the antibody’s ability to eliminate target cells and provide therapeutic benefits.

Activity of Imvotamab Biosimilar

Imvotamab Biosimilar exerts its therapeutic effects by binding to the CD3E and MS4A1 proteins on the surface of T cells. CD3E is a component of the T cell receptor complex, while MS4A1 is a co-stimulatory molecule. By binding to these proteins, Imvotamab Biosimilar activates T cells and triggers an immune response against target cells, such as cancer cells or cells involved in autoimmune diseases.

Imvotamab Biosimilar also has the ability to induce immune tolerance, which is important for the treatment of autoimmune diseases. By binding to CD3E and MS4A1, Imvotamab Biosimilar can suppress the activity of autoreactive T cells and prevent them from attacking healthy tissues.

Applications of Imvotamab Biosimilar

Imvotamab Biosimilar has a wide range of potential applications in the field of immunotherapy. Its ability to target and activate T cells makes it a promising candidate for the treatment of various cancers, including hematological malignancies and solid tumors. Imvotamab Biosimilar can also be used in combination with other anti- cancer therapies to enhance their efficacy.

In addition to cancer treatment, Imvotamab Biosimilar has shown promising results in the treatment of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. Its ability to induce immune tolerance makes it a potential alternative to current treatments, which often have significant side effects.

Conclusion

In summary, Imvotamab Biosimilar is a novel anti-CD3E,MS4A1 monoclonal antibody with a similar structure and activity to the well-known OKT3 antibody. Its unique ability to activate T cells and induce immune tolerance makes it a promising therapeutic agent for the treatment of various diseases. With ongoing research and clinical trials, Imvotamab Biosimilar has the potential to revolutionize the field of immunotherapy and improve the lives of patients with cancer and autoimmune diseases.

ProteoGenix catalogue number PX-TA1848. For research use only.

Target: Imvotamab Biosimilar – Anti-CD3E;MS4A1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet